Send to

Choose Destination
See comment in PubMed Commons below
Nano Lett. 2014 Jun 11;14(6):3023-32. doi: 10.1021/nl404360k. Epub 2014 Feb 6.

Dual-porosity hollow nanoparticles for the immunoprotection and delivery of nonhuman enzymes.

Author information

Department of Electrical and Computer Engineering, ‡UC San Diego Moores Cancer Center, §Department of Bioengineering, ∥Department of Chemistry and Biochemistry, ⊥Howard Hughes Medical Institute and Department of Pharmacology, and ¶Department of Nanoengineering, University of California , San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States.


Although enzymes of nonhuman origin have been studied for a variety of therapeutic and diagnostic applications, their use has been limited by the immune responses generated against them. The described dual-porosity hollow nanoparticle platform obviates immune attack on nonhuman enzymes paving the way to in vivo applications including enzyme-prodrug therapies and enzymatic depletion of tumor nutrients. This platform is manufactured with a versatile, scalable, and robust fabrication method. It efficiently encapsulates macromolecular cargos filled through mesopores into a hollow interior, shielding them from antibodies and proteases once the mesopores are sealed with nanoporous material. The nanoporous shell allows small molecule diffusion allowing interaction with the large macromolecular payload in the hollow center. The approach has been validated in vivo using l-asparaginase to achieve l-asparagine depletion in the presence of neutralizing antibodies.

[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Chemical Society Icon for PubMed Central
    Loading ...
    Support Center